Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 Shares

Edwards Lifesciences Co. (NYSE:EWGet Free Report) VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The sale was disclosed in a filing with the SEC, which is available through this link.

Edwards Lifesciences Trading Up 0.3 %

Shares of EW stock opened at $93.78 on Thursday. The company has a market cap of $56.51 billion, a P/E ratio of 40.42, a PEG ratio of 3.36 and a beta of 1.11. The stock has a 50 day simple moving average of $88.70 and a two-hundred day simple moving average of $86.21. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Research analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $86.00 to $103.00 in a report on Tuesday, May 14th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Mizuho raised their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Finally, Stifel Nicolaus increased their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $95.18.

View Our Latest Stock Analysis on Edwards Lifesciences

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in the business. Park Avenue Securities LLC grew its stake in Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock valued at $2,169,000 after acquiring an additional 108 shares during the period. Martin Capital Advisors LLP grew its stake in Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after acquiring an additional 128 shares during the period. City State Bank grew its stake in Edwards Lifesciences by 16.5% in the second quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after acquiring an additional 130 shares during the period. Legacy Wealth Asset Management LLC grew its stake in Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 134 shares during the period. Finally, Chapin Davis Inc. boosted its position in shares of Edwards Lifesciences by 1.7% during the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after buying an additional 140 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

See Also

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.